Pfizer heart-failure drug helps milder patients: study

2010-11-144

Advertisement

résuméCHICAGO People with mild heart failure lived longer and fared better by adding Pfizer's drug Inspra to standard medications, a finding that could widely expand use of such drugs in healthier patients, researchers said on Sunday. In an ironic twist, a

Advertisement

CHICAGO People with mild heart failure lived longer and fared better by adding Pfizer's drug Inspra to standard medications, a finding that could widely expand use of such drugs in healthier patients, researchers said on Sunday.

In an ironic twist, another study presented at the American Heart Association meeting showed Johnson & Johnson's Natrecor heart failure drug -- which is not widely used because of long-standing safety concerns -- is in fact safe, but provides little benefit.

Nearly 5 million Americans have heart failure, a chronic condition that costs the United States an estimated $30 billion a year to manage. Unlike a heart attack, in which a heart artery becomes blocked, heart failure is gradual. It occurs when the heart loses its ability to efficiently pump blood.

Patients taking Inspra along with standard treatment were 37 percent less likely to die or be hospitalized for heart failure compared with those who were taking standard treatment alone, Dr. Faiez Zannad, a researcher from France's Henri Poincare University of Nancy, told the meeting.

He said the results were in line with strong results seen in previous trials of Inspra in sicker heart failure patients and now should expand the drug's use to those with milder disease.

The latest trial was stopped in May when it became clear that it would succeed.

Inspra, which is sold under the generic name eplerenone, is a member of the family of medicines called aldosterone antagonists that also includes an older generic drug called spironolactone. They block a hormone that the body uses to hold onto salt.

The new study should greatly expand the use of this family of drugs, Zannad said.

"Now we are filling the gap and we have all the continuum of heart failure -- after a heart attack, among the most severe patients, and now mild patients are eligible," Zannad said.

Inspra is currently approved for patients that have had a heart attack and have heart failure. Spironolactone is approved for patients with severe heart failure.

For mild heart failure, patients typically now take drugs known as beta blockers and ACE inhibitors, two standard medicines. Zannad predicted aldosterone antagonists will now be added to their drug regimens.

A second study presented at the meeting answered some lingering questions about J&J's heart drug Natrecor, whose use plunged in 2005 after several studies suggested it could damage the kidneys.

J&J, which in 2003 acquired Natrecor through its $2.4 billion purchase of biotech company Scios Inc, fought hard to counter the negative findings, but most doctors stopped prescribing it.

J&J continues to sell the product, but doctors say the company does not actively market the niche drug.

Researchers on Sunday said a trial sponsored by J&J surprisingly showed the medicine does not harm the kidneys, as earlier studies suggested, but is minimally effective at helping people with heart failure.

A big former use of the medicine was frequent infusions among patients treated outside of the hospital, even though the drug was not approved for that population.

"There is no patient who should receive intermittent infusion," Dr. Clyde Yancy of Baylor University Medical Center in Dallas, told the meeting.

"The trial provided very little evidence that its addition would improve the outcome of patients with acute decompensated heart failure who are receiving excellent standard of care," said Dr. Eugene Braunwald of Harvard University.

He said the study "... joins a large number of other trials conducted with a variety of agents since the 1970s in acute heart failure that have not shown a clinical benefit. How to improve outcomes in this very common condition remains a significant challenge."

CHICAGO People with mild heart failure lived longer and fared better by adding Pfizer's drug Inspra to standard medications, a finding that could widely expand use of such drugs in healthier patients, researchers said on Sunday. In an ironic twist, a

PARIS An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market. Although Eliquis will be third

n">Bayer will move a heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular treatments after the experimental medicine showed a "striking" reduction in deaths in a mid-stage trial. Having done wel

LONDON Expectations are building for a new heart failure drug from Novartis viewed as a likely multibillion-dollar seller, with two surveys of cardiologists published on Tuesday highlighting its potential. A large clinical trial with LCZ696 was stopp

n">An experimental once-a-week drug for type 2 diabetes being developed by Merck & Co proved effective in lowering blood sugar levels in a mid-stage clinical trial, according to data presented on Wednesday. The pill, known as MK-3102, is from

n">Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse. The trial was testing the drug Inlyta in patients who have

ZURICH U.S. health regulators turned down an application to approve Novartis' experimental heart failure drug due to insufficient evidence that it improves symptoms, the Swiss drugmaker said on Friday. Novartis said in a statement the Food and Drug A

ZURICH EU health regulators have recommended against approving Novartis's experimental heart failure drug for the second time this year due to insufficient evidence it improves symptoms, the Swiss drugmaker said in a statement on Friday. The ruling b

BASEL, Switzerland Novartis plans to test a novel pricing model with some customers when it launches its keenly awaited new heart failure drug Entresto, the Swiss company's head of pharmaceuticals said on Tuesday. Entresto, also known as LCZ696, is t

ZURICH Novartis said it would ask the European health regulator to look at its heart failure drug serelaxin again after the body took an unfavorable position on it Friday. "Novartis announced today it will shortly submit a revised filing package, inc

n">Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday. In the st

LONDON Healthy, middle-aged smokers who take Pfizer's Chantix or Champix, one of the most popular quit-smoking drugs, have a higher risk of suffering heart attacks or other serious heart problems, a study found on Monday. British and American scienti

n">Pfizer Inc's Xalkori delayed progression of lung cancer longer than chemotherapy in patients who had never previously been treated for the disease, according to results of a late-stage study released on Tuesday. The medicine, which received U.S

CHICAGO An experimental heart failure medicine from Novartis that previously showed it reduced death and hospitalizations also curtailed worsening of symptoms, need for additional therapy and emergency room visits, adding to evidence that it will bec

n">Amgen Inc and Cytokinetics Inc said on Tuesday their experimental drug for chronic heart failure showed significant improvement in cardiac function in the second part of a mid-stage study. The 448 patients in the trial were given an oral formul

n">Pfizer Inc said on Friday that a late-stage trial of its drug for renal cell cancer failed to meet its main goal when given in combination with Avastin, a drug made by Roche Holding AG. Pfizer's drug Torisel is approved as a single agent for th

DALLAS A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alter

n">Pfizer Inc on Monday said one of its experimental drugs had failed to meet its goals in two late-stage studies among patients who had received prior treatment for advanced non-small cell lung cancer, the most common form of the disease. Althoug

WASHINGTON A drug to treat acute heart failure made by Novartis AG should not be approved because there is insufficient evidence to show it improves symptoms, according to an initial review by the U.S. Food and Drug Administration. The review, posted

LONDON European regulators have lifted a warning on Pfizer's smoking cessation drug Champix - called Chantix in the United States - after a clinical study concluded it did not appear to increase the risk of neuropsychiatric side effects. Champix is a